The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
COlorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study (NRG- GI004/SWOG-S1610): A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC).
 
James J. Lee
Consulting or Advisory Role - Incyte; Loxo
Research Funding - Incyte; Merck
 
Greg Yothers
Employment - Mountainview Pediatrics (I)
Consulting or Advisory Role - Orbus Therapeutics; Pharmacyclics
 
Samuel A. Jacobs
No Relationships to Disclose
 
Hanna Kelly Sanoff
Research Funding - Bayer (Inst); Merck (Inst)
 
Deirdre Jill Cohen
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Merck Sharp & Dohme; Taiho Pharmaceutical; Vicus Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Merck (Inst)
 
Katherine A Guthrie
No Relationships to Disclose
 
Norah Lynn Henry
Research Funding - Abbvie (Inst); BioMarin (Inst); Innocrin Pharma (Inst); Pfizer (Inst)
 
Patricia A. Ganz
Leadership - Intrinsic LifeSciences (I)
Stock and Other Ownership Interests - Abbott Laboratories; GlaxoSmithKline; Intrinsic LifeSciences (I); Johnson & Johnson; Merck; Novartis; Pfizer; Silarus Therapeutics (I); Teva; xenon pharma (I)
Honoraria - Biogen (I)
Consulting or Advisory Role - Gilead Sciences (I); InformedDNA; Keryx (I); La Jolla Pharma (I); Lilly; Silarus Therapeutics (I); Vifor Pharma (I)
Research Funding - Keryx (I)
Patents, Royalties, Other Intellectual Property - related to iron metabolism and the anemia of chronic disease (I); Up-to-Date royalties for section editor on survivorship
Travel, Accommodations, Expenses - Intrinsic LifeSciences (I); Keryx (I)
 
Scott Kopetz
Stock and Other Ownership Interests - MolecularMatch; Navire
Consulting or Advisory Role - Amal Therapeutics; Biocartis; EMD Serono; Genentech; Holy Stone Healthcare; Holy Stone Healthcare; Karyopharm Therapeutics; Merck; Navire; Roche; Symphogen
Research Funding - Amgen (Inst); Array BioPharma (Inst); Biocartis (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Guardant Health (Inst); MedImmune (Inst); Novartis (Inst); Sanofi (Inst)
 
Peter C. Lucas
Stock and Other Ownership Interests - Amgen
Consulting or Advisory Role - Bayer (I)
 
Carmen Joseph Allegra
No Relationships to Disclose
 
Charles David Blanke
No Relationships to Disclose
 
Norman Wolmark
Research Funding - AstraZeneca/MedImmune (Inst)
Travel, Accommodations, Expenses - China-American Summit; Genentech; Genomic Health
 
Howard S. Hochster
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; Sirtex Medical
 
Thomas J. George
Consulting or Advisory Role - Merck
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Pharmacyclics (Inst); Tesaro (Inst)
 
Michael J. Overman
Consulting or Advisory Role - Bristol-Myers Squibb; Gritstone Bio; MedImmune; Roche/Genentech
Research Funding - Bristol-Myers Squibb; MedImmune; Merck; Roche